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Abstract
Potent cytolytic peptides with specific tethering and cloaking sites have been synthesised and used to release payload from liposomes in a
quantitative manner. A functionally located cloaking site has been modified specifically by simple conjugation without adversely affecting
the cytolytic properties of the peptide. The cytolytic activity of modified peptides was then efficiently ( > 98%) cloaked and uncloaked by
ligand–protein or hapten–antibody interactions. The principle of a dual response peptide has been demonstrated using an avidin-cloaked pH-
sensitive peptide. Biospecific cloaking/uncloaking provided a new sensitive (f 12 pmol) homogeneous diagnostic and also appears
potentially suited to bioresponsively targeted release of antimicrobial, anticancer and other drugs now delivered using liposomes. D 2002
Elsevier Science B.V. All rights reserved.
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1. Introduction
Potent cytolytic peptides are found widely from insects to
mammals, particularly as antimicrobial peptides or defen-
sins [1], where they are involved as venoms and in innate
defence at mucosal membranes [2] and as cytolysins in
lymphocytes [3]. In order to target and localise their other-
wise catholic action, their biological delivery is tightly
controlled at the cellular and molecular levels (e.g., activat-
ing synthesis, release from lysosomes, cleavage of pro-
peptides). While inactive peptides such as prodefensins have
now been cloned, proteolytic cleavage provides limited
specificity. It has not proved possible to exploit directly
the more sophisticated mechanisms available within cells.
Mimics of such smart biological behaviour may provide
new directions for targeted therapy and sensitive diagnos-
tics, but despite extensive study of the structural basis of
action of some cytolytic peptides [4,5], this has proved
difficult and has limited their exploitation. In natural cyto-
lytic peptide sequences the potential to adopt an amphi-
pathic a-helical conformation and the presence of net
positive charge are prominent features required to permea-
bilise membranes, while a number of other factors, includ-
ing affinity for the phospholipids, ability to penetrate the
lipid acyl chain region and the actual orientation within the
bilayer, may influence the actual mode of action. Additional
interactions come into play when phospholipid-associated
peptides self-associate to produce larger aggregates resulting
in pore formation. The precise details of mechanism are
unclear, even for the most extensively studied peptide,
melittin, as uncertainties remain concerning its membrane
bound aggregation state [6]. Typically, as in the case of
melittin, the positively charged end of the peptide makes an
electrostatic contact with the phospholipid resulting in the
amphiphilic alpha helical conformation embedding into the
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lipid. This amphiphilic structure, with its flexible hinge in
the central part of the molecule and unordered C-terminal
end, has axis parallel to the plane of the membrane with
polar face towards the lipid head group and hydrophobic
face somewhat residing into the bilayer. In one model, this
alone leads to lysis by disruption of the phospholipid
structure, while in another model aqueous channels are
formed by the peptide chains associating into oligomers
that span the membrane in perpendicular orientation (Fig.
1). Liposomes have been more widely used in drug delivery
[7,8] than diagnostic applications [9,10] or as in vivo
imaging agents [11]. While there has been extensive study
of lipid formulations [12], attempts to accomplish controlled
and quantitative release of payload in response to biospe-
cific triggers have been limited. Liposomes have been
considered for homogenous immunoassay using comple-
ment-mediated lysis but such assays proved unreliable as
any one of the many labile components of complement
could become inactivated [10,12,13]. Homogeneous lip-
osomal immunoassay using nonspecifically labelled melittin
as the lytic agent was reported as an alternative to the
complement assay [14–16]. However, the solubility of
melittin–hapten conjugates and the preservation of their
lytic activity posed problems that restricted consideration
largely to digoxin assay [12,17–19]. Lysyl, found in the
cationic site, critical for lytic activity [4,5,20], are the key
residues affected by hapten conjugation. Owing to such
difficulties of using natural peptides, others have used
conjugates with the larger enzymic cytolysin, phospholipase
C, nonspecifically labelled with analytes [19,21]. While
such conjugates had superior solubility and greater retention
of activity after modification, only 75% to 85% of their
activity was specifically inhibited in the presence of anti-
serum.
Broad-ranging analyte-specific release of marker mole-
cules with insignificant nonspecific background leakage has
not been achieved by either approach. Consequently, only
the heterogeneous liposomal assay configurations have
approached the necessary sensitivity and reliability [22].
Time-resolved fluorimetry has improved the nonspecific
background and sensitivity problems to some extent by
encapsulating a larger molecular weight protein chelator
conjugate in liposomes, providing more specific fluorescent
detection upon cytolysin-mediated complexation with ions
such as Eu3 + [17]. However, nonspecific lysis by unin-
hibited conjugates presented a variable nonspecific back-
ground, which, combined with the reduced activity of
conjugates, would undermine the sensitivity and reliability
of such assays.
In order to overcome these problems and to develop a
simple to use and self-contained system, we report the
design of potent unnatural cytolytic peptides, which can
be cloaked effectively (to provide stable insignificant activ-
ity) and activated quantitatively, including by co-activation
of cloaked peptides using both pH and ligand binding
reactions. Structural and covalent modifications at such a
cloaking site would prevent the cytolytic action of the
peptides on biomembranes by one or more mechanisms
(Fig. 1), including: pH and redox titration, ligand and steric
hindrance (e.g., by antibodies, avidin). When this is
reversed by back titration of the ionisable groups, and/or
by release of the bound protein or enzymatic cleavage of the
cloaking moiety, biomembranes would be permeabilised to
both small and large molecules. The requirement for more
than one biospecific response to activate such peptides
would be expected to improve the fidelity or specificity of
the process. In principle, any combination could be used to
permeabilise cells or to control the release of diagnostic or
therapeutic payloads from liposomes. Such biospecific
release may be particularly suited to antimicrobial, anti-
cancer and the increasing range of other drugs now deliv-
ered in liposomes.
Fig. 1. Schematic illustration of the concept of synthetic cloaked peptides. Integration of peptide assemblies into lipid bilayer is effected by the introduction of
an uncharged N terminus forming a tethering site. The cloaking site is regiospecifically located at a position, near the central region of the peptide, most likely
to affect its function quantitatively by affinity binding reactions. A line has been drawn to show the polar–apolar interface. Mechanisms involved in activating
such peptides could include steric, pH, redox and enzymatic cleavage reactions or a combination for multiple-activation with the result that dissociation of the
cloaking molecule(s) frees and presence of activation conditions enables the cytolytic peptide to breach the membrane.
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2. Materials and methods
2.1. Peptide synthesis
Peptides (Table 1) were manually synthesised by solid
phase t-Boc chemistry using 0.5 mmol of p-methylbenzhy-
drylamine (MBHA) resin. Amino acid (BACHEM, UK)
side chain protections were 2-chlorobenzyloxycarbonyl for
lysine; p-toluenesulfonyl for arginine; and benzyl for threo-
nine, serine and glutamic acid. Couplings were conducted
over 40 min using 1.5 mmol of amino acid, 1.5 mmol of
BOP and 4.5 mmol of DIPEA in N,N dimethylformamide
(DMF). Repeat couplings were used, when necessary, to
drive the reaction almost to completion (>99.8%). N-acety-
lation was carried out over 30 min using acetic anhydride
(0.5 M) and pyridine (0.5 M) in DMF. Coupling of 2,4,6-
trinitrophenyl (TNP) to the N terminus was achieved by
treatment for 14 h with a 10-fold molar excess of 2,4,6-
trinitobenzene sulfonic acid (TNBS) in DMF. Myristic acid
was coupled in the same manner as an amino acid. At the
end of synthesis, peptides were cleaved from the resin using
hydrogen fluoride (HF) in the presence of 0.5 g p-thiocresol
and 0.75 g p-cresol as scavengers. The peptides were
purified on a C-4 reverse phase semi-preparative column
(Vydac C-4, 250 4.6 mm) using an acetonitrile/0.1% TFA
gradient. The purity of the peptides was estimated by
analytical reverse phase high performance liquid chroma-
tography (HPLC). No peptides below the 95% purity level
were used. Peptides were characterised using electrospray or
MALDI mass spectrometry. All methods were performed at
room temperature.
2.2. Chemically modified peptides
For biotinylation, peptides (20 Amol) were dissolved in 4
ml DMF, when biotin N-hydroxysuccinimide (100 Amol),
followed by DIPEA (300 Amol), were added and reaction
allowed to proceed with stirring for 3 h. TNP modification
was achieved by dissolving peptide (20 Amol) in 4 ml of
DMF containing TNBS (2 mmol) and stirring for 14 h.
Generic peptide (5.3 Amol) to be modified with pentaery-
thritol tetranitrate (PETN) analogue (trinitropentaerythritol
hemisuccinyl) was added to a total volume of 2.3 ml in
DMF/dimethylsulfoxide (DMSO) (65:35 v/v ratio, respec-
Table 1
Primary sequences of synthetic peptides and structural modifications
Peptide Sequence
(1) Melittin GIGAVLKVLTTGLPALISWIKRKRQQ-NH2
(2) Generic Acetyl-GIGAVLRVLTTGKPALISWIRRRRQQ-NH2
(3) M-generic Myr-GIGAVLRVLTTGKPALISWIRRRRQQ-NH2
(4) pH hybrid Myr-EAALAEALAEALAEGKPALISWIRRRLQQ-NH2
(5) M16 Myr-LLRLLLKLLLLRLLR-NH2
Peptides analogues were specifically modified on single Lys q-amino located near the centre of the sequence, with the exception of natural melittin which has
multiple labelling sites including the N-terminal amino.
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tively) containing 3 equivalents of each of the following:
trinitropentaerythritol hemisuccinate [23], hydroxybenzo-
triazole (HOBT) and diisopropylcarbodiimide (DIC)
(Sigma). In all of these preparations, reactions were allowed
to proceed to completion, as monitored by a decline of
amine content using ninhydrin assays. The biotin and TNP
reactions reached completion overnight, while the PETN
analogue reaction proceeded to completion after 1 h. Resid-
ual solvent from the reaction mixtures was then removed
under vacuum and the product was purified by reverse phase
HPLC on a C-4 preparative column using acetonitrile and
0.1% TFA gradients. Peptides were characterised by mass
spectrometry as above. All methods were performed at room
temperature.
2.3. Liposomes
Liposomes encapsulating 120 mM calcein were prepared
by extrusion (Avestin Liposofast 100) at room temperature
using 2:1 molar ratio of phosphatidylcholine and cholesterol
passed 10 times through 0.2-Am polycarbonate filters
(Nucleopore). The nonencapsulated dye was removed by
gel filtration, through a PD-10 column (Pharmacia), using
iso-osmotic eluting buffer. The total lipid concentration of
the preparation was measured by the Stewart assay and
adjusted to 3 mg/ml. The average liposome diameter (typ-
ically 175 nm) and polydispersity (typically 0.07) was
estimated by photon correlation spectroscopy (Malvern
4700).
2.4. Cloaking/uncloaking assays
Peptides were prepared at concentrations ranging from 1
to 0.01 mg/ml, depending upon the activity of the particular
peptide. Melittin, nonspecifically labelled with TNP, was
only sparingly soluble in water and was prepared in 25% (v/
v) DMSO in water. Avidin (5 units per ml; 1 unit of avidin
binding 1 Ag of biotin) was prepared in PBS pH 7.4 buffer.
Biotin, PETN and 2,4,6-trinitrotoluene (TNT) solutions (10
mg/ml in DMSO) were diluted using water to obtain work-
ing concentrations of 1 Ag/ml. Typically, assays were
performed at room temperature in a total volume of 2 ml
containing calcein liposomes (5 AM lipid). Calcein release
was monitored by fluorescence emission at 520 nm follow-
ing excitation at 490 nm using a Perkin Elmer LS-50B
fluorimeter. Avidin was incubated with biotin for 2 min
prior to addition of biotinylated peptide (44 nM), when after
further 2 min, liposomes (7 AM lipid) were added. No biotin
was added when peptide (2.8 nM) was to be cloaked by a
1.2-fold excess of avidin, which was pre-incubated for a
minimum of 3 min. TNT and PETN assays were conducted
in a similar manner, replacing biotinylated peptide with
trinitropentaerythritol hemisuccinyl and TNP-labelled pep-
tides, and avidin with monoclonal (supplied by Defence
Evaluation and Research Agency, Kent, UK) anti-TNT and
anti-PETN antibodies [23] and incubating for 5 rather than 2
min. The antibody titre necessary was pre-determined by
titration of the peptide concentration with antibody until
insignificant (or no further reduction in) peptide activity
could be achieved (e.g., for TNT, 30 Al antibody for 7.4 nM
peptide; for PETN, 20 Al antibody for 7.7 nM peptide). To
evaluate the dual response properties of biotinylated hybrid
peptides, calcein liposomes (7 AM lipid) in 2 ml of buffer
were treated with peptide (2.8 nM) and the fluorescence
monitored as before.
2.5. Nitroavidin–peptide complex
Nitroavidin was prepared and nonmodified sites were
blocked with biotin [24]. Biotinylated peptide was incubated
with a threefold molar excess of nitroavidin in PBS pH 7.4
for 30 min, when excess biotinylated peptide was exhaus-
tively dialysed against PBS for 24 h (retaining approxi-
mately 2 mg protein/ml as estimated by BCA assay, Pierce).
As calcein release assays indicated residual contamination
from free peptide, nitroavidin–peptide complexes were
further purified by gel filtration on a Sephadex G-50
(Pharmacia) column (22 2 cm) equilibrated with PBS
pH 7.4 buffer. Early fractions (0.5 ml), with activity in the
presence of biotin but little or no activity in its absence,
were pooled (recovering approximately 0.4 mg protein/ml
as estimated by BCA assay). Biotin (0.4 Amol) displacement
of nitroavidin was performed by adding 0.6 ml of the pooled
nitroavidin–peptide complex fraction to 2 ml of PBS pH 7
buffer containing calcein liposomes (2 AM lipid). All
methods were performed at room temperature.
3. Results
The sequences of peptides and structure of labels con-
jugated at cloaking sites via the single free q-amino group
are given in Table 1. The calculated and expected mass
values were found to agree within 0.8 of a unit, within the
accuracy of the mass spectrometer using external calibra-
tion. The HPLC purity was above 95%. The conjugates of
the peptides were also purified to homogeneity and charac-
terised in the same way with the exception of nonspecifi-
cally labelled TNP–melittin, which presents four primary
amino groups as potential conjugation sites. Consequently,
treatment of this peptide with 2,4,6-trinitobenzenesulfonic
acid (TNBS) in solution phase produced a heterogeneous
mixture of products with significantly reduced potency and
low aqueous solubility. Using a molar extinction coefficient
of 10550 cm  1 M  1 for the q-amino TNP product [25],
the nonspecifically labelled conjugate had on average 3.6
TNP groups per melittin monomer. TNP-labelled melittin
exhibited lytic activity, which was many orders of magni-
tude lower than the parent peptide (Table 2). Due to the low
solubility of the peptide, higher concentrations could not be
tested; turbidity was apparent and light scattering interfered
with fluorescent measurements. In contrast, regiospecific
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coupling of the TNP group to the N terminus by solid phase
methods gave a homogeneous product, whose activity
although largely retained (Table 2), could not be diminished
significantly in the presence of anti-TNP (Fig. 4). Typically,
more than 60% of liposome contents were released by the
peptide in the presence of anti-TNP antibody. It did not
prove possible to produce any melittin conjugate that
retained sufficient activity, which was blocked in the pres-
ence of excess antibody. Consequently, various synthetic
structures were prepared with a single modification site. The
activity of such a ‘generic’ peptide (Table 2) was about 14-
fold lower than melittin. However, this was not such a large
loss in activity as when Leucine 13 residue was completely
eliminated [26]. When Lysine 13 of the generic peptide was
modified with a relatively nonpolar group, to produce
biotinylated generic peptide, a significant increase in activ-
ity was observed (Table 2). ‘M-generic’ peptide with a N-
terminal myristoyl (Myr) (Table 2) exhibited lytic activity
near equivalent to melittin. M-generic peptide also retained
adequate lytic activity following biotinylation. Furthermore,
its activity was insignificant in the presence of avidin (Fig.
2). In the presence of biotin, however, quantitative recovery
of lytic activity was observed (Figs. 2 and 3). In typical
assays, 20 pmol of biotin could be rapidly and reliably
detected in 2-ml volume (Fig. 3). The potential may exist to
increase the assay sensitivity by using liposomes with lower
cholesterol content, requiring lower peptide (to lipid ratios)
to release liposome contents.
The ability to achieve further specificities was illustrated
by coupling trinitropentaerythritol hemisuccinate and TNP
to the q amino group of Lysine 13 of the ‘generic and M-
generic’ peptides (Fig. 3), respectively. In both cases,
cloaking of the modified peptides with specific antibodies
was almost complete with very little residual or background
activity (Fig. 4). In the presence of analyte, however,
quantitative recovery of lytic activity proved possible with
detection sensitivity in the nM range.
Since in all cases, when using different labels (biotin,
TNP and trinitropentaerythritol hemisuccinyl), the peptide
remained active against liposomes and the activity could be
almost completely switched off in the presence of the
relevant binding protein; the same approach was applied
to two further cytolytic peptide structures. Again, using
avidin binding to biotinylated peptides 4 and 5 (Table 1),
efficient cloaking could be achieved with low uncloaked
background activity (Fig. 4). Comparing the residual activ-
Fig. 2. Cloaking and uncloaking the activity of biotinylated M-generic peptide. Progress of lysis of calcein liposomes (7 AM lipid) upon addition (at
approximately 2 min) to 2-ml peptide solution (44 nM) in PBS buffer pH 7.4 containing avidin (1.2-fold excess) with various concentrations of biotin. The top
trace represents lysis by peptide while the bottom trace represents background fluorescence in the absence of any peptide. The remaining curves (bottom to top)
represent biotin concentrations of 0, 10, 20, 30, 50 and 100 nM.
Table 2
Relative cytolytic activities of synthetic peptides and their modified
analogues
Peptide EC50 [nM]
Melittin 22
N-terminal labelled TNP-melittin 16
Nonspecifically labelled TNP-melittin >103
Generic 312
M-generic 18
Biotinylated M-generic 29
Biotinylated generic 72
The percentage lysis was measured using various peptide concentrations
(ranging from 1 nM to 10 AM) in 2 ml of PBS pH 7.4 containing calcein
liposomes at 5 AM lipid concentration. Lysis was calculated by measuring
the fluorescent signal 3 min after addition of liposomes and expressing the
value as a percentage of that observed upon addition of 0.1% Triton X-100.
Replicate studies were within 2% variation. The EC50 value represents the
peptide concentration required to cause 50% release of signal.
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ity of all the cloaked peptides in this study (Fig. 4), we note
that the uncloaked background activity was generally low
( < 2% release of liposome contents in most cases) and,
more importantly, the small initial release that does occur
remained almost unchanged during the course of assays. In
contrast, when the natural sequence of melittin, regiospecifi-
cally labelled at the N terminal, was used, there was a high
level of residual activity, which approached 80% release of
liposome contents within 6 min.
In order to develop a single peptide–liposome reagent, it
is essential to integrate the cloaked peptide within each
liposome particle, while retaining the payload, and demon-
strate uncloaking of peptide activity by displacement of the
bound protein to release the liposome contents. Nitroavidin
has been shown to bind biotin in a reversible manner [24].
Biotinylated peptide 2 (Table 1) was cloaked by incubation
with nitroavidin and integrated into liposomes. These nitro-
avidin-cloaked peptide–liposome complexes remained sta-
ble over long incubation times, when rapid uncloaking
could be achieved by the addition of biotin (Fig. 5). In this
manner, one-step and one-pot assay configurations could be
achieved. Competitive reactions could also be considered,
particularly when the affinity or immuno-specific trigger is
armed by another mechanism (e.g., pH), which would also
be expected to improve the practicality of homogeneous
assays. A biotinylated pH-sensitive peptide was developed,
which was a hybrid of cationic and anionic sequences
(peptide 4 in Table 1). This peptide, in its unmodified form,
exhibited pH-sensitive activity, depending upon the level
(peptide-to-lipid ratio) used. Upon modification with biotin,
the peptide retained its activity and pH-responsive proper-
ties, preferentially activating at mildly acidic pH values with
only slight activity at pH 8 (Fig. 6). While the peptide could
be efficiently cloaked upon avidin binding, liposomes could
only be triggered to release at acidic pH in the presence of
biotin (Fig. 6). The potential would now exist to prepare
other dually responsive peptides, requiring both (not either)
reactions to activate.
Bioaffinity reactions have proved to be particularly
useful in biosensors and diagnostic tests [27]. In the above
assays, affinity cloaking was performed competitively in
the presence of various levels of analyte, and quantitative
release of fluorescent signal from liposomes could be
monitored in the presence of a few nanograms of analyte.
A simple fluorescent test taking a few minutes to perform
was developed to enable signal to be observed with the
naked eye. To a glass vial containing 1.1 ml of calcein
liposomes (4 AM lipid) in PBS pH 6.2 buffer was added a
mixture of 12 pmol biotin, 17 pmol of peptide (peptide 4 in
Table 1) and 1.2-fold excess of avidin premixed in 100 Al
of PBS pH 8 buffer. The contents were rapidly mixed
simply by inverting the vial three times. The vial was then
illuminated from below by a 3-mm blue light-emitting
diode. Within 5 min of mixing the analyte and reagent,
green fluorescence became clearly visible compared to the
reagent background signal (without biotin), which had no
or negligible intensity that remained constant, allowing
Fig. 3. Response curves for Biotin, TNT and PETN. For biotin curve (n)
the data from Fig. 2 was used taking the top and bottom curves to represent
100% and 0% lysis, respectively. The percentage lysis was then calculated 5
min after addition of liposomes. For TNT and PETN the percentage lysis
was estimated 3 min after the addition of calcein liposomes (1 AM lipid) to
2-ml PBS buffer pH 7.4 containing various concentrations of TNT (E)
incubated with 30 Al of monoclonal anti-TNT, and M-generic TNP peptide
(7.4 nM); PETN (.) incubated with 20 Al of monoclonal anti-PETN and
trinitropentaerythritol hemisuccinyl-generic peptide (7.4 nM). Each deter-
mination was conducted in triplicate.
Fig. 4. Residual activity after cloaking of peptides. Liposomes were added
to biotin-, TNP- and trinitropentaerythritol hemisuccinyl-labelled peptides
pre-incubated with avidin, anti-TNT or anti-PETN antibody (respectively)
in 2 ml of PBS buffer pH 7.4. Residual activity was estimated as a
percentage of activity relative to uncloaked peptide in the absence of
binding proteins at 3 (5) and 6 (n) min after addition of liposomes. In the
case of biotinylated peptides, 1.2-fold excess units of avidin were used to
block the peptides: (1) N-terminally labelled TNP melittin (7.4 nM) and
anti-TNT 30 Al, 1 AM lipid; (2) biotinylated M-generic peptide (50 nM) and
7 AM lipid; (3) TNP-labelled M-generic peptide (7.4 nM), anti-TNT (30 Al)
and 1 AM lipid; (4) biotinylated generic peptide (16 nM) and 2.1 AM lipid;
(5) biotinylated M16 R peptide (300 nM) and 7 AM lipid; (6)
trinitropentaerythritol hemisuccinyl-labelled generic peptide (7.7 nM), 20
Al anti-PETN and 1 AM lipid; (7) biotinylated-hybrid (2.8 nM) peptide and
7 AM lipid.
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detection of 12 pmol of biotin rapidly and without any
instrumentation.
4. Discussion
Many natural cytolysins are known to comprise the
common feature of a cationic site [28] critical for lytic
activity [4,5,20]. It is clear that such cytolysins could not be
labelled nonspecifically at multiple sites and still retain
activity, nor could efficient cloaking at those sites be
achieved. Such modifications appear to impose major and
variable alterations on the structure and hydrophobicity of
the peptides. In the case of nonspecifically TNP-labelled
melittin, the lytic activity became poor (Table 2). This
appears to agree with earlier studies, particularly that the
elimination of positive charge by chemical modification of
melittin resulted in an almost total loss of lytic activity for
succinylated melittin [29], a melittin analogue whose pos-
itively charged Lysine 7 was replaced with a neutral leucine
residue [30], permethylated melittin [31] and dimethylated
melittin showing 70% loss in activity [32]. The solubility of
conjugates produced when melittin is nonspecifically
labelled is typically very low, as found here for TNP–
melittin. In the case of the earlier digoxin assay, this was
overcome by conjugation of a more soluble oubain analogue
[16]. Similar observations have been made for other com-
monly used labels such as 4-nitro-7-cholorobenzofurazan
(NBD), fluorescamine and 2-chloro-3,5-dinitrobenzoic acid,
where nonspecific labelling even at a 1:1 molar ratio
produced insoluble products [33]. Although the nature of
the labelling group was different, a similar trend was
observed to that shown by Ius et al. [17], who showed that
the conjugation of a 2:2 molar ratio of estriol rendered
melittin 95% inactive, while at a 1:1 molar ratio, the loss in
Fig. 5. Uncloaking of peptide by ligand displacement. Nitroavidin–biotinylated generic peptide complex (0.32 mg protein) incubated in 2 ml of PBS
containing calcein liposomes (2 AM lipid) was treated with excess biotin (0.4 Amol). The fluorescent lower trace shows the equivalent level of liposomes alone
to indicate the background fluorescence.
Fig. 6. Suppression of residual cloaked activity with pH. pH-dependent
lysis by 2 ml of biotinylated hybrid peptide (2.8 nM) under acidic and
alkaline conditions in PBS containing calcein liposomes (7 AM lipid): (a)
traces from top to bottom represent (i) peptide at pH 6.6, (ii) peptide at pH 8
and (iii) background signal in the absence of any peptide; (b) traces from
top to bottom represent peptide in the presence of (i) 11 pmol of biotin and
1.2-fold excess of avidin at pH 6.6, (ii) 1.2-fold excess of avidin at pH 6.6,
(iii) 11 pmol of biotin and 1.2-fold excess of avidin at pH 8 and (iv) 1.2-fold
excess of avidin at pH 8.
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activity was 32%. Specific formylation of melittin at its N
terminus had little effect on the activity [5], in line with
studies here for N-terminally labelled TNP–melittin.
Unfortunately, N-terminally labelled melittin could not be
efficiently prevented (Fig. 4) from lysing liposomes in the
presence of anti-TNP, rendering this site unsuitable for
cloaking. As the lytic activity is largely retained, the data
does, however, suggest that this part of the molecule may be
suitable for tethering the peptide. Fatty acid modification at
this position also improved activity and favoured insertion
of such peptides into membranes.
The major obstacles associated with use of natural
cytolysins can be overcome by engineering generic peptide
structures devoid of their natural primary amino groups and
provided with specific cloaking and tethering sites. These
peptides were designed to meet several criteria. (i) The
cationic character was maintained, as it appears critical for
activity and solubility. (ii) Multiple primary amino groups
were eliminated to allow regiospecific conjugation of mol-
ecules by common chemical procedures, post-synthetically,
in 1:1 stoichiometric ratio at sites suitable for cloaking and
tethering. (iii) The cloaking site was located at a position
most likely to render the peptide conjugate active prior to
protein binding and insignificantly active when noncova-
lently bound to larger proteins. (iv) The tethering site was
designed to facilitate integration of the cytolytic peptide
with biomembranes in the cloaked state and enhance its
potency.
In the case of melittin, and indeed many other natural
peptides, contradictory mechanisms appear in the literature
regarding the orientation of the peptide, with respect to the
lipid bilayer, which can be ‘‘wedgelike’’ or transbilayer
[20,34]. In the wedge model, both termini are located
outside the lipid bilayer, while in the transbilayer model
the N-terminal inserts. In all cases, however, the central
peptide segment is unambiguously shown to reside in the
interior of the bilayer, making this the most suitable part of
the molecule for cloaking purposes. On the other hand, the
relatively hydrophobic nature of the N terminus formed a
suitable tethering site where fatty acid could be attached to
allow formation of an integrated complex with the bilayer of
liposomes [35]. The replacement of lysines by arginines,
substitution of Leu 13 by lysine and introduction of Myr
residue at the N terminus appeared to fulfil such criteria.
Due to its importance to lytic activity and its occupancy near
the polar apolar interface [36], Leu 13 appears to be a good
choice for sensitive modification of bilayer partitioning of
the peptide on protein binding. It is noteworthy though that
this residue has been shown to be one of the key residues,
along with Trp 19, with respect to lytic activity, indicating
that any changes at such positions must be as subtle as
possible. The conformation of melittin is often described as
helix–bend–helix. To minimally interfere with either of the
helices, and to avoid significant alterations in steric effects,
the Leu 13 residue was substituted with Lys in the unstruc-
tured bend, which incorporates residues 11 to 14 (hinge
region) with a 120–160j kink near Threonine 11 and
Glycine 12 [36–38]. In the absence of substantial structural
changes, the lower activity observed for the generic peptide
may simply be a result of introducing a charged residue into
an apolar face of the molecule, thereby affecting its overall
amphiphilicity. When this residue was modified with a
relatively nonpolar group to produce biotinylated generic
peptide, a modest increase in activity was observed. Similar
modification with other haptens (TNP and trinitropentaery-
thritol succinyl) resulted in conjugates, which were active
and could be inhibited efficiently by antibody binding (Fig.
4) with quantitative recovery of activity in the presence of
respective analytes (Fig. 3). For these conjugates, the
sensitivity levels were in the nanomolar range (Fig. 3).
Further improvements can be expected by increasing lytic
activity of peptides, as was the case with M-generic peptide,
which detected biotin in the picomole range. Transport of
unmodified Lysine 13 across the bilayer without deproto-
nation would be energetically unfavourable. The free energy
gain by fatty acid-assisted partitioning of N terminus in the
case of M-generic peptide may be large enough to compen-
sate for the deprotonation of Lysine 13. The binding and
insertion of the N-terminal region of melittin appears
primarily driven by hydrophobic effects [39]. This may
explain the enhanced activity of the M-generic structure,
which was equivalent to that of melittin, and the ability to
cloak and uncloak the peptide. Despite the high level of
inhibition of the biotinylated M-generic peptide activity
with avidin and no discernible activity of the cloaked
peptide after lengthy incubation with liposomes, its activity
was quantitatively and rapidly recovered in the presence of
biotin (Fig. 2) by competitive and displacement reactions.
With the dually responsive peptide, both affinity reaction
and low pH were necessary to release liposomal contents
(Fig. 6). Reliance on any one step, with a small but none-
theless significant level of nonspecific triggering, would
result in greater nonspecific release. Particularly in the case
of amplified cascade mechanisms or peptide– liposome
complexes, the dual response offers potential benefits in
both diagnostic and potential drug delivery applications,
where low levels of release would be more significant. This
approach enabled a simpler assay with well-controlled
background. Peptides cloaked in this way may be useful
for producing biosensing assemblies to operate at the sub-
micron scale and also for the bioresponsive release of drugs.
In conclusion, the major reason why cytolytic peptides
have found very limited applications in controlling the
release of liposome contents is because it has not been
possible to control and target their activity in a specific and
facile manner. Consequently, despite a wide range of studies
on their properties and action, application of cytolytic
peptides has been limited to topical and disinfection treat-
ments and a liposomal immunoassay—almost forgotten
because of its unreliability and restricted specificity. Using
peptides specifically designed for cloaking, the range of
specificities as well as fidelity of responsive release from
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liposomes may be improved and diversified for: (a) sensitive
and simple diagnostic tests and rapid screening procedures;
(b) in vivo diagnostics and therapeutics, for the active
targeting of specific regions or cells (e.g., cancer, micro-
organism, cellular immune system); and (c) the biorespon-
sive delivery of drugs, where their scope for smart materials
to mimic biological behaviour has been recently discussed
[40]. Particularly by their integration into liposomes, to form
stable and responsive sub-micron biosensor assemblies, the
biospecific uncloaking of lipopeptide assemblies appears to
provide a new direction for in vitro and in vivo diagnostics.
Bioresponsive peptide– liposomes are small assemblies,
which could be more easily and effectively introduced than
any present biosensor concepts to sense locally and operate
at the microscopic level. Studies are currently underway to
release liposome-encapsulated anticancer drugs in the vicin-
ity of tumours using cloaked peptides.
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